Skip to the page

Data / Drug companies / Provepharm Inc.

Provepharm Inc.: 13 products in the FDA NDC directory, labeler code 81284

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Provepharm Inc. (labeler code 81284) lists 13 products in the FDA National Drug Code Directory, covering 6 finished drugs by generic name. By type: 13 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 5, 2023.

The request: Watch Provepharm Inc. (FDA labeler code 81284): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
81284
Products in commercial distribution
13
Packages
14
Finished drugs by generic name
6
Prescription products
13
Over the counter products
0
Flagged as original packager
13 of 13 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
August 1, 2019
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)1184.6%
New drug applications (NDA)17.7%
Unapproved drugs for a shortage17.7%

Products by type

TypeProductsShare
Prescription drugs13100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection, powder, lyophilized, for solution538.5%
Injection538.5%
Injection, solution323.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Anticholium81284-831InjectionUnapproved drugs for a shortageOctober 5, 2023
Piperacillin and Tazobactam81284-154Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)January 11, 2023
Bludigo81284-315InjectionNew drug applications (NDA)September 6, 2022
Tranexamic acid81284-612Injection, solutionGeneric drugs (ANDA)September 30, 2021
Tranexamic acid81284-611Injection, solutionGeneric drugs (ANDA)September 30, 2021
Dihydroergotamine Mesylate81284-411Injection, solutionGeneric drugs (ANDA)September 30, 2021
Phenylephrine hydrochloride81284-213InjectionGeneric drugs (ANDA)August 12, 2020
Phenylephrine hydrochloride81284-212InjectionGeneric drugs (ANDA)August 12, 2020
Phenylephrine hydrochloride81284-211InjectionGeneric drugs (ANDA)August 12, 2020
Piperacillin and Tazobactam81284-155Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)August 1, 2019
Piperacillin and tazobactam81284-153Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)August 1, 2019
Piperacillin and tazobactam81284-152Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)August 1, 2019
Piperacillin and tazobactam81284-151Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)August 1, 2019

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.